Contenu disponible en anglais seulement.
Bulletin de la Bourse
Appili Therapeutics Inc. (APLI) inscrit à la Bourse de Toronto
14 septembre 2020
| Issuer: | Appili Therapeutics Inc. ("Appili") |
| Security: | Class A common shares (the "Common Shares") |
| Symbol: | APLI |
| Number of securities issued and outstanding: | 61,604,011 Common Shares |
| Number of securities reserved for issuance: | 25,330,929 Common Shares |
| Listing category: | Industrial, Non-Exempt Issuer |
| Trading currency: | CDN$ |
| Listing and posted for trading date: | September 16, 2020 (at the opening) |
| Other market(s): | The Common Shares have been listed on TSX Venture Exchange ("TSXV") since June 25, 2019 under the symbol "APLI". The Common Shares will be delisted from TSXV on September 16, 2020, upon commencement of trading on Toronto Stock Exchange. |
| Temporary market maker: | Canaccord Genuity Corp. |
| Security ownership registration: | Certificated Issue & Direct Registration System |
| Investor relations: | Ms. Kimberly Stephens (902) 442-4655, ext. 2 Email: kstephens@appilitherapeutics.com Mr. Armand Balboni (902) 442-4655, ext. 1 Email: abalboni@appilitherapeutics.com |
| Incorporation: | Canada Business Corporations Act |
| Fiscal year end: | March 31 |
| Nature of business: | Appili is a pharmaceutical company focused on the acquisition and development of novel medicines targeting unmet needs in infectious disease. Since incorporation in 2015, Appili has been focused on building and advancing a diverse portfolio of anti-infective programs. |
| Transfer agent and registrar: | Computershare Investor Services Inc. at its principal offices in Montréal and Toronto |
| Dividends: | Appili does not expect to declare dividends in the foreseeable future. |
| Sponsorship: | Not applicable |
| TSX contact: | Chris Birkett, Managing Director, Toronto Stock Exchange |
